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130 Poster Session-IISR-GVHD, defined as lack of response or disease progression after
at least 7 days of treatment with methylprednisolone at 2 mg/kg. Be-
tween 3/2003 and 6/2008, 20 patients with advanced SR-GVHD fol-
lowing allogeneic transplantation were treated with DD at OHSU, 7
afterMRD and 13 after URD (six matched, one A antigenmismatch,
and six allele mismatch) .GVHD prophylaxis consisted of cyclo-
psporine, methotrexate, and steroid (19) or cyclosporine plus
MMF (1). Nineteen patients developed acute SR-GVHD overall
grade III (7) and IV (12) while one patient developed chronic exten-
sive SR-GVHD. Twelve patients received DD as first salvage ther-
apy while 8 patients were treated with other agents prior to DD (6
had one and 2 had two prior salvage therapies including MMF and
Etanercept). Planned treatment was DD at a dose of 600 mcg
(9mcg/kg) on days 1, 3, 5, 15, 17, and 19.Median days toDD therapy
after stem cell transplant was 38.Ten patients showed response (4CR
and 6 PR defined as at least a one overall grade improvement), six
were non responders, and four patients died before completion of
treatment. One patient remains alive. Causes of death included
GVHD (8), opportunistic infection (5), respiratory failure (2), trans-
plant-associated microangiopathy (2), ICH (1), and relapse (1). Me-
dian survival for the entire group was 30.5 days from the onset of DD
(4–18391) with median survival of 116 days for patients who re-
ceived all 6 doses of DD. Despite measurable responses in 50% of
patients, no survival benefit was observed. Profound immune sup-
pression was significant among responders, contributing to opportu-
nistic infection and death. Thus, DD may be most beneficial if used
earlier in the course or in lower grade aGVHD. Responses can be
achieved in advanced SR-GVHDwithDDbut novel approaches still
remain the research target for these patients given poor overall
survival .362
EVALUATION OF ALLOIMMUNE RESPONSES IN HUMANIZED NOD/SCID/
IL2RGNULL MICE FOLLOWING HUMAN CD341 STEM CELL TRANSPLAN-
TATION
Hartwig, U.F.1, Hemmerling, J.1, Hoffmann, J.1, Andre, M.C.2,
Handgretinger, R.2, Huber, C.1, Herr, W.1, Meyer, R.G.1 1Johannes
Gutenberg-University School of Medicine,Mainz, Germany; 2Eberhard--
Karls University School of Medicine, Tuebingen, Germany
Immunodeficient NOD/SCID/IL2Rg (yc)null mice can be effi-
ciently used to establish human lymphohematopoiesis or lymphohe-
matological neoplasia in a murine environment. Thus, upon
engraftment of human CD341 hematopoietic stem cells (HSC) or
acute leukemia cells and allogeneic donor lymphocyte infusions
these mice might become a powerful tool to provide an allogeneic
HSCT model for investigating human graft-vs-host (GvH)- and
graft-vs-leukemia (GvL)-immunity in vivo. In the current study,
we engrafted NOD/SCID/ycnull mice with human CD341 HSC to
provide a model for analyzing the role of patient-derived antigen
presenting cells for the induction of GvH- and GvL-reactivity and
to evaluate reactivity to human alloantigens of ex vivo engineered
T cell allografts for improved immunotherapy. Following reconsti-
tution of busulfan conditioned neonatal or (300 cGy) irradiated adult
NOD/SCID/ycnull recipients with 1  105 to 1  106 purified
CD341 adult HSC and weekly i.v. injections of Fc-IL7, human
CD451 PBMNC were detected as early as early as 30 or 60 days
(d) post reconstitution of newborn and adult mice, respectively. After
120d, T-, B-, and NK-cells, as well as monocytes and dendritic cells
(DCs) were found in spleen (SPL) and bonemarrow of both newborn
and adult recipients by flow cytometry and immunhistological stud-
ies in e.g. SPL and skin. However, as reconstitution of newborns re-
sulted in thymopoiesis of human CD31 cells and better lympho- and
myelopoiesis as compared to adult mice, further studies were per-
formed in HSC engrafted newborn recipients. Functional analyses
of lymphocytes grown in humanized NOD/SCID/ycnull mice re-
vealed that human CD31 T cells isolated from SPL and challenged
ex vivo with i) murineNOD/SCID/ycnull derivedDCs, ii) HLA-mis-
matched DCs or iii) HSC donor derived (autologous) DCs elicited
alloresponses to human but not murine alloantigens(s). These results
and further studies on ex vivo examined allo- and xenoimmunity of
naı¨ve HLA-matched and HLA-mismatched CD81 T cells trans-
ferred into HSC engrafted NOD/SCID/ycnull recipients will be pre-
sented to demonstrate T cell alloimmune responses in humanized
mice and to show that our model can be used to evaluate residualGvH reactivity of CD81 donor T cells in HLA- matched or haploi-
dentical settings. Finally, these studies should help to elucidate the
impact of xenoreactivity on the induction of GvH immunity by hu-
man T cells in humanized mice.363
PROPHYLACTIC ADMINISTRATION OF EX VIVO CO-STIMULATED DONOR
LYMPHOCYTE INFUSION (DLI) FROM RELATED AND UNRELATED
DONORS AFTER REDUCED INTENSITY CONDITIONING FOR HIGH RISK
HEMATOLOGIC MALIGNANCIES
Goldstein, S.C., Levine, B., Smith, J., Hinkle, J., Luger, S., Perl, A.,
Loren, A., Frey, N., Stadtmauer, E., Porter, D.L., June, C.H. University
of Pennsylvania, Philadelphia, PA
Enhancing the graft versus tumor (GvT) effect without graft ver-
sus host disease (GvHD) is critical to the success of reduced intensity
(RIC) strategies for allogeneic transplantation. Despite establishing
donor lymphohematopoiesis, relapse rates remain high. Standard
DLI given at relapse or prophylactically to enhance donor chimerism
has met with limited success in improving transplant outcomes. Co-
stimulation of donor T-cells, using anti-CD3/CD28 coated beads to
serve as artificial APCs, may reverse functional T cell tolerance,
thereby restoring immune responsiveness and potentiate GVT. Un-
like standardDLI, ex vivo co-stimulationmay enhanceT cell activity
by removing and activating T cells outside of a tumor-induced im-
munosuppressive milieu. We report the preliminary results of a fea-
sibility trial of ex vivo co-stimulated DLI from sibling and unrelated
donors given ‘prophylactically’ at 4 and 6 months after RIC alloge-
neic transplantation for patients (pts) with high-risk hematologic
malignancy.
Methods: 15 pts have undergone RICwith alemtuzumab, Fludar-
abine,Busulfan with peripheral blood stem cell transplantation
(PBSCT) and planned activated DLI (pADLI) at 4 months (1 
107 CD31/kg) and 6 months (1  108 CD31/kg) post-transplant
in the absence of GvHD or relapse. All pts received tacrolimus and
methotrexate as GvHD prophylaxis.
Results: 8 pts (AML, n5 6; ALLCR1 n5 2) received grafts from
HLA-identical sibling donors, 7 (AML n5 5;MDS n5 1; ALL, n5
1) from matched unrelated donors. Donor hematopoiesis was estab-
lished in all patients. Of the 11 infusions given to date, there has been
no infusion-related toxicity, confirming the safety and feasibility of
this strategy. 8 pts have received the first of 2 planned infusions of
pADLI. Of the remaining 7 pts, 4 infusions are upcoming, 1 was pre-
cluded by early relapse, and 2 were precluded by early NRRM. Of
the 8 pts who received their initial pADLI#1, 3 have received a second
infusion. 5 pts did not receive pADLI#2 because of relapse (n 5 3),
GvHD (n5 1), and transient uveitis in the absence ofGvHD (n5 1).
Overall incidence of acute GvHD (aGvHD) has been low; 1 pt devel-
oped aGvHD prior to pADLI#1, and 1 pt developed aGvHD after
pADLI #1. No patient has developed chronic GvHD.
Conclusion: Preliminary results of this trial demonstrates that
RIC with PBSCT followed by ex vivo costimulated pADLI for
poor prognosis hematologic malignancies is safe and feasible with
potential for enhancing GvT without increasing GvHD.364
CLINICAL EXPANSION OF CORD BLOOD DERIVED T CELLS FOR USE AS
DONOR LYMPHOCYTE INFUSION AFTER CORD BLOOD TRANSPLANTA-
TION
Okas, M.1,2, Gertow, J.1,2, Uzunel, M.1, Karlsson, H.1, Uzunel, M.1,
Ringden, O.1,2, Mattsson, J.1,2, Uhlin, M.1,2 1Karolinska Institutet,
Stockholm, Sweden; 2Karolinska University Hospital, Stockholm, Sweden
Background: When no HLA-identical donor is available, cord
blood transplantation (CBT) is an attractive option due to the rapid
availability of the graft and its biological properties. One of the dis-
advantages associated with CBT is lack of possibility for donor lym-
phocyte infusion (DLI) after CBT. Here we report expansion and
characterization of CD3 positive lymphocytes from CB grafts in
connection to CBT.
Material andMethods:Lymphocytes from 13 CB grafts were ex-
panded with CD3/CD28 beads and 200 IU/ml rIL2. Expanded cells
were cryopreserved in ready-to-use DLI doses. Immunophenotyp-
ing and cytokine production assay were performed on expanded
Poster Session-II 131CB and ex vivo CB as well as peripheral blood mononuclear cells
(PBMC) as controls. T cell receptor spectratyping was performed
before and after expansion with aim to determine usage of different
TCR Vbetas.
Results:T cells expanded with a median of 148-fold over a period
of 8–11 days. Expanded preparations contained 99% of CD31 cells
without signs for significant expansion of CD191 or CD3-/CD561
cells. CD4/CD8 ratio of expanded T cells was not altered signifi-
cantly when compared to CB ex vivo (a mean of 1,7 to 2,02, respec-
tively). The majority of T cells were positive for ab T cell receptor
(93%). Up to 85% of expanded T cells were CD251, 3% of
CD31 fraction were CD251/FoxP31. Expanded T cells, when
stimulated with CD3-beads, produced IL-2, IFN-g, TNF-a in
a cell to bead ratio in a dose-dependantmanner at higher levels, com-
paraed to peripheral T cells and CB ex vivo T cells. TCR spectratyp-
ing has shown a polyclonal pattern of TCR Vbeta-gene usage in the
expanded T cell pool.
Conclusions:We have successfully set up a clinically feasible sys-
tem of T cell expansion for use as DLI after CBT. The expansion
procedure has not introduced major phenotypic changes when com-
pared to CB cells ex vivo. Expanded cells are functional in terms of
cytokine production and display no oligoclonal pattern of TCR us-
age. Expanded CB T lymphocytes may serve as a possibility for DLI
after CBT.365
GRAFT-VERSUS-HOST REACTIONS TARGET HEMATOLYMPHOID ORGANS
LEADING TO ALTERATIONS IN HEMATOPOIETIC RECONSTITUTION AND
DYSFUNCTIONAL IMMUNITY
Mueller, A.M.S.1,2, Allen, J.A.1, Berry, K.A.1, Miklos, D.1,
Shizuru, J.A.1 1Stanford School of Medicine, Stanford, CA; 2University
Medical Center Freiburg, Freiburg i.Br., Germany
The pathophysiology of chronic (c) Graft-versus-Host Disease
(GVHD) is poorly understood. The protean nature of the syn-
drome suggests more complex mechanisms than pure T cell (TC)
effects. We analyzed cellular infiltrates of hematolymphoid tissues
(bone marrow (BM), spleen, lymph nodes (LN), thymus, liver) after
hematopoietic cell transplantation (HCT) in 3 minor-mismatched
mouse models of GVHD. Myeloablated BALB.B (H2b), BALB/c
(H2d), and BALB.K (H2k) mice were given purified hematopoietic
stem cells 1 splenocytes (SP) from C57BL/6 (B6), B10.D2, or
AKR/J donors, respectively. BALB.B recipients developed acute
and chronic GVHD. BALB/c mice showed skin lesions on ears
and tail, which resolved by d50, but no systemic or late symptoms.
Despite a lower SP dose BALB.K hosts developed fulminant
GVHD. Differences in type and kinetics of cellular infiltration of
organs were observed between the strains. In all 3 models BM
was a major site of donor (do) TC infiltration early post-HCT.
While B cell (BC) reconsititution was severely delayed BALB.B
BM contained 50% doTC, which were in 60% CD81 (effector
memory (EM) phenotype), and H60 tetramer-reactive in up to
24%. At a low level doTC persisted long-term in the BM.
BALB/c recipients of B10.D2 grafts had better BC regeneration
and less infiltrating doTC (40%). The latter were CD4/8 balanced
and normalized promptly (d50 \3%). In contrast, BALB.K mice
given AKR/J grafts, had prominent CD4 (EM) doTC infiltrates.
The liver was a main target of GVH in BALB.B recipients: 14d
post-HCT liver MNC contained 60–80% doTC, 30% reactive to
H60. Low levels of infiltration were observed long-term. In
BALB/c livers Mac1/Gr11 cells predominated (\60%), while
doTC infiltration was less severe and resolved completely. BALB.K
livers contained 80% doTC, mostly CD41. Thymuses, spleen
and LN of BALB.B and K recipients were hypoplastic, hypocellular
and infiltrated by doTC with a decreased CD4/811 fraction.
BALB.K LN had predominantly CD4 doTC and lacked BC, while
BALB.B LN contained CD8.CD4. Thymuses, spleen and LN of
BALB/c recipients normalized after some initial doTC infiltration.
In conclusion, hematolymphoid organs can be GVH targets, which
is associated with impaired hematopoietic and immune reconstitu-
tion. Damage of these tissues may disturb normal immunity, and
via dysfunctional immune education indirectly contribute to auto-
immune-like phenomena as seen in chronic GVHD.366
FEASABILITY OF EXTRACORPOREAL PHOTOPHERESIS IN MANAGING PA-
TIENTS WITH BRONCHIOLITIS OBLITERANS FOLLOWING ALLOGENEIC
STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE
Rome, A.M., Toor, A.A., Chung, H., Roseff, S.D., Edwards, R.,
Lamberta, J., Anderson, J., Candler, K., McCarty, J.M. Virginia Com-
monwealth University, Richmond, VA
Introduction: Bronchiolitis obliterans (BO) is a serious, often fa-
tal complication of allogeneic stem cell transplantation (SCT). Most
patients do not respond to conventional immunosuppressive ther-
apy.We retrospectively reviewed records of patients with BO treated
with extracorporeal photopheresis (ECP), given its efficacy in man-
aging chronic corticosteroid refractory cutaneous, oral, and hepatic
graft versus host disease (GVHD).
Patients and Methods: Forty two patients were treated at our
center for chronic GVHDwith ECP from 2003–2007. Thirteen pa-
tients (31%)met diagnostic criteria for BO defined as the presence of
pulmonary symptoms, hypoxemia and one of the following 1) de-
crease in FEV1 by.20% or 2) air-trapping, small airway thickening
or bronchiectasis on lung CT without evidence of an infection. ECP
was performed on 2 consecutive days every 2 weeks for the first 4
months and less frequently thereafter.
Results: Nine of thirteen patients met criteria due to decrease in
FEV1 and lung changes onCT; 4 due to radiographic findings alone.
ECPwas initiated at a median of 954 days (range, 173–2122 days) af-
ter allogeneic SCT (11 matched related donors, 2 unrelated donors).
All but one patient had failed prior corticosteroid-based immuno-
suppressive therapy. With a median follow-up of 782 days from di-
agnosis of BO, 11/13 (85%) of the patients are alive. Seven of
thirteen (54%) patients had a 50%decrease in steroid dosagewithout
deterioration of pulmonary function; 3/13 (23%) patients had im-
provement of radiographic abnormalities; 4/7 (57%) patients with
oxygen requirements prior to initiation of ECP were completely ti-
trated off oxygen. No patients had a decline in pulmonary function
tests despite steroid withdrawal. Only 3 patients experienced grade
III or higher adverse events related to the indwelling catheter (3 in-
fectious, 1 bleeding and 2 thromboses). Two of thirteen patients
died, one due to progression of BO and 1 from pneumonia. Our ob-
served survival rate of 85% in patients with BO is in contrast to the
44–73% survival rate noted in prior studies using treatment with
conventional immunosuppressive therapy.
Conclusion: In this retrospective study, we demonstrate the fea-
sibility of using ECP to manage BO occurring after allogeneic
SCT. ECP should be considered as early second-line therapy in pa-
tients developing BO following SCT; however, further study is war-
ranted to confirm these results.367
BONE MARROW AND INTESTINAL BUT NOT PERIPHERAL BLOOD EOSIN-
OPHILIA PREDICTS ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) AF-
TER HEMATOPOETIC STEM CELL TRANSPLANTATION WITH REDUCED
INTENSITY CONDITIONING (RIC-HCT)
Rosch, P.1, Aigner, T.2, Franke, G.1, Lange, T.1, Niederwieser, D.1,
Basara, N.1 1University of Leipzig, Leipzig, Germany; 2University of
Leipzig, Leipzig, Germany
Objectives: Acute GvHD remains a severe complication after
RIC-HCT. We report here the predictive value of bone marrow
and intestinal eosinophilia in patients transplanted from 1999 to
2005 by using RIC HCT.
Patients andmethods:One hundred and fifteen patients (55 fe-
male) with haematological malignancies with the median age of 59
years (range 21 to 75) were treated with RIC-HCT for AML (n 5
76), ALL (n 5 7), CML (n 5 13) and MDS (n 5 19). Condition-
ing regimen consisted of fludarabine at day -4 to -2 and 2 Gy total
body irradiation at day 0 followed by the infusion of HCT of an
related (n 5 30), allele matched unrelated (n 5 76) or mismatched
(n 5 9) donor and treatment with MMF and CSA. Bone marrow
and peripheral blood evaluation was performed before and on day
128 after RIC-SCT; Eosinophilia was graduated from 0 to 4. Sys-
tematic colon and/or duodenal biopsies have been performed im-
mediately after first symptoms of gut GvHD. Histological criteria
of gut GvHD were assessed and tissue eosinophils analysed within
the lamina propria and lamina submucosa. The density of
